Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS G12C Mutant Solid Tumors
Carcinoma, Non-Small Cell Lung
Carcinoma, Non-Small-Cell Lung
Non-Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Nonsmall Cell Lung Cancer
Colorectal Cancer
Colorectal Carcinoma
Colorectal Neoplasms
Colorectal Tumors
Neoplasms, Colorectal

Interventions

DRUG: JDQ443
DRUG: trametinib
DRUG: Ribociclib
BIOLOGICAL: cetuximab

Sponsor

Novartis Pharmaceuticals